COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)					1 Months Ended		9 Months Ended
	Jan. 05, 2024	Oct. 04, 2023	Feb. 02, 2023	Jan. 11, 2022	Apr. 24, 2024	May 30, 2019	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2019	Dec. 10, 2015
First payment owed				$ 145,000			$ 0
Accrued Interest							79,492
Recognized loss on contingency							(323,184)
Consultant remuneration per month							3,500
Costs and attorneys' fees							$ 332,503
Compensation for services, description							As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a remuneration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month
Charles River Laboratories, Inc. [Member]
Remaining commitment							$ 28,936
Payment of amended consideration						$ 3,024,476
BICX Holding Company LLC [Member]
Common stock issued upon convertible debt							2,227,575
Convertible Promissory Note									$ 4,160,000
Conversion agreement description							Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment. As of September 30, 2024, the Public Offering has not yet been abandoned by the Company
Issuance price							$ 2.00
Orange County Research Center [Member]
Consideration amount				$ 657,640			$ 503,089
Pellecome [Member]
Attorney's fees							$ 235,886
Attorney's fees received or awarded	$ 332,503	$ 222,933	$ 222,933
Interest rate							10.00%
Pellecome [Member] \| January 5, 2024 [Member]
Attorney's fees received or awarded							$ 332,503
Consultant [Member]
Renumeration amount							$ 1,417
Issue of common stock to consultant							3,000
Alpine Creek [Member]
Royalty due							$ 91	$ 91
Total consideration amount							1,531,926	$ 1,531,926
Payables to Alpine Creek										$ 1,215,000
Paid to Alpine Creek							$ 1,620,000
Payable commitment description							On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. On or about January 1, 2021, Mr. Galligan acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek
Payable per treatment sold										$ 100
Profit holding percentage										50.00%
Mr Lucido [Member]
Accrued Interest					$ 7,858
Mr Lucido [Member] \| January 5 2024 [Member]
Annual compensation	$ 200,000

BioCorRx Inc. 10-Q